STAINES-UPON-THAMES, United Kingdom, Oct. 21, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global
biopharmaceutical company, is proud to celebrate Respiratory Care
Week (October 20-26, 2019), and honor
the role of respiratory therapists in providing critical care to
patients in respiratory distress.
There are more than 134,000 respiratory therapists in the U.S.
Respiratory therapists work closely as part of medical teams to
evaluate, treat and care for patients with breathing or other
cardiopulmonary disorders. With more than 80 percent working in
hospital settings, they play critical roles in neonatal intensive
care units (NICU), emergency rooms, air transport and other areas
of acute and critical care.
"Treating respiratory conditions requires in-depth medical
knowledge and a sophisticated understanding of respiratory devices.
We commend the respiratory therapists for their ability to act fast
when critical moments arise," said Tunde
Otulana, M.D. Senior Vice President and Chief Medical
Officer of Mallinckrodt.
Respiratory therapists work with some of the most vulnerable
patients in the hospital, such as term and near-term neonates with
hypoxic respiratory failure (HRF) resulting from persistent
pulmonary hypertension of the newborn (PPHN), a serious
cardiorespiratory complication that can occur after birth.
Respiratory therapists are also a vital part of transport teams
that treat critically ill patients in emergency transit to critical
care units, operating rooms and other centers of care.
Mallinckrodt is the maker of
INOmax® (nitric oxide) gas for inhalation, indicated in
the U.S. to improve oxygenation and reduce the need for
extracorporeal membrane oxygenation in term and near-term (>34
weeks gestation) neonates with hypoxic respiratory failure
associated with clinical or echocardiographic evidence of pulmonary
hypertension in conjunction with ventilatory support and other
appropriate agents.
INOmax nitric oxide product is distributed with INOmax delivery
systems. INOmax Total Care® is a comprehensive
platform inclusive of drug, device, service and disposables that
includes regular maintenance, quality assessment and quality
control; physician and clinician device training; 24/7/365 customer
and technical support; and rapid response of product availability
in an emergency, to help mitigate abrupt discontinuation of
INOmax.
Respiratory Care Week is sponsored by the American
Association for Respiratory Care (AARC). For more information,
visit
http://www.aarc.org/resources/programs-projects/respiratory-care-week/.
About INOmax®
In the U.S., INOmax is
indicated to improve oxygenation and reduce the need for
extracorporeal membrane oxygenation in term and near-term (>34
weeks gestation) neonates with HRF associated with clinical or
echocardiographic evidence of pulmonary hypertension in conjunction
with ventilatory support and other appropriate agents. For more
information, visit https://www.inomax.com/.
Important Safety Information
- INOmax is contraindicated in the treatment of neonates
dependent on right-to-left shunting of blood.
- Abrupt discontinuation of INOmax may lead to increasing
pulmonary artery pressure and worsening oxygenation.
- Methemoglobinemia and NO2 levels are dose
dependent. Nitric oxide donor compounds may have an additive effect
with INOmax on the risk of developing methemoglobinemia. Nitrogen
dioxide may cause airway inflammation and damage to lung
tissues.
- In patients with pre-existing left ventricular dysfunction,
INOmax may increase pulmonary capillary wedge pressure leading to
pulmonary edema.
- Monitor for PaO2, inspired NO2, and
methemoglobin during INOmax administration.
- INOmax must be administered using a
calibrated, FDA-cleared Nitric Oxide Delivery System.
Please see U.S. Full Prescribing
Information.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple
wholly owned subsidiaries that develop, manufacture, market and
distribute specialty pharmaceutical products and therapies. The
company's Specialty Brands reportable segment's areas of focus
include autoimmune and rare diseases in specialty areas like
neurology, rheumatology, nephrology, pulmonology and ophthalmology;
immunotherapy and neonatal respiratory critical care therapies;
analgesics and gastrointestinal products. Its Specialty Generics
reportable segment includes specialty generic drugs and active
pharmaceutical ingredients. To learn more about Mallinckrodt,
visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution
of important company information, such as press releases, investor
presentations and other financial information. It also uses its
website to expedite public access to time-critical information
regarding the company in advance of or in lieu of distributing a
press release or a filing with the U.S. Securities and
Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Trade Media
Caren Begun
Green Room Communications
201-396-8551
caren@greenroompr.com
Financial/General Media
Daniel
Yunger
Kekst CNC
212-521-4879
mallinckrodt@kekstcnc.com
Investor Relations
Daniel J.
Speciale, CPA
Vice President, Investor Relations and IRO
314-654-3638
daniel.speciale@mnk.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners.
© 2019 Mallinckrodt. US-1901906
10/19
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-raises-awareness-of-critical-role-respiratory-therapists-play-in-patient-care-during-respiratory-care-week-300942308.html
SOURCE Mallinckrodt plc